Key Highlights

  • Jaguar Health (NASDAQ:JAGX) dropped 25.05% to USD 0.6626 ahead of a November 6, 2026 debt-for-equity vote.
  • TriSalus Life Sciences (NASDAQ:TLSI) slid 15.70% to USD 3.06.
  • Arcadia Biosciences (NASDAQ:RKDA) fell 10.77% to USD 0.1392.
  • Niki BioSolutions (NASDAQ:NIKI) lost 8.28% to USD 1.55.
  • Medicus Pharma (NASDAQ:MDCX) declined 11.92% to USD 1.70 after a 50-to-1 share consolidation on October 12, 2026.
  • Senti Biosciences (NASDAQ:SNTI) dropped 16.06% to USD 0.1578 after a Merger closed with contingent value rights only.

Jaguar Health (NASDAQ:JAGX) (down USD 0.2215, 25.05%): Dilution Looms Before the Stockholder Vote

Jaguar Health (NASDAQ:JAGX) dropped 25.05% to USD 0.6626 in premarket trading on November 3, 2026, implying a November 2 close near USD 0.88 (calculated). No press release dated November 2 or 3, 2026 was identified as the trigger.

Stockholders will vote on exchanging about USD 2,895,351 of Debt and Series Q preferred stock for common stock. At an illustrative minimum price of USD 7.06, a full exchange would issue 3,596,425 shares, against 1,945,542 outstanding on September 25, 2026. At USD 1.00 the figure would be 25,390,851 shares. A USD 75 million shelf was filed on October 22, 2026.

TriSalus Life Sciences (NASDAQ:TLSI) (down USD 0.5699, 15.70%): A Drop With No Fresh Headline

TriSalus Life Sciences (NASDAQ:TLSI) slid 15.70% to USD 3.06 in premarket trading on November 3, 2026. No announcement dated October 30 to November 3, 2026 was identified, and no cause can be confirmed.

The August 6, 2026 release showed second-quarter Revenue of USD 11.4 million, up 1.7%, with a net loss of USD 9.2 million. Full-year 2026 revenue guidance of USD 54 million to USD 57 million was maintained, which leaves the second half carrying the weight. Cash was USD 46.3 million against long-term debt of USD 33.1 million.

Arcadia Biosciences (NASDAQ:RKDA) (down USD 0.0168, 10.77%): Going Concern Doubt and a Possible Reverse Split

Arcadia Biosciences (NASDAQ:RKDA) fell 10.77% to USD 0.1392 in premarket trading on November 3, 2026. No announcement dated October 30 to November 3, 2026 was identified.

The company now centers on Zola coconut water. Its Annual Report filed March 26, 2026 stated that substantial doubt exists about its ability to continue as a going concern, with an accumulated Deficit of USD 281.2 million. Cash was USD 4.2 million at June 30, 2026 after a USD 4 million private placement. Stockholders approved a reverse split of one-for-2 to one-for-10. The screen price sits far below the roughly USD 1.03 per share calculated from the June placement, so the quote needs care.

Niki BioSolutions (NASDAQ:NIKI) (down USD 0.1399, 8.28%): Alzheimer's Diagnostics and a Tiny Share Count

Niki BioSolutions (NASDAQ:NIKI) lost 8.28% to USD 1.55 in premarket trading on November 3, 2026, implying a Monday close of about USD 1.69 (calculated). No release or filing dated November 2 or 3, 2026 was identified. A move of this size on small Volume can come from a handful of orders, which is an inference, not a confirmed cause.

The company, formerly Aptorum Group Limited, combined with DiamiR Biosciences and announced a plasma based APOE genotyping Partnership on October 14, 2026. A USD 75 million shelf could dilute holders.

Medicus Pharma (NASDAQ:MDCX) (down USD 0.2301, 11.92%): Consolidation Now, Possible Reversal Later

Medicus Pharma (NASDAQ:MDCX) declined 11.92% to USD 1.70 in premarket trading on November 3, 2026, implying a prior close near USD 1.93 (calculated). No announcement dated November 2 or 3, 2026 was identified, and the fall looks like continued Volatility after the consolidation.

Nasdaq confirmed bid price compliance on October 23, 2026, though continued compliance is not guaranteed. A proxy statement asks shareholders to approve a split of up to 50 post-split shares for each pre-split share at a December 2, 2026 meeting, which could reverse the consolidation. On September 2, 2026 the company entered an agreement with Pfizer (NYSE:PFE) covering CD228V, with a USD 12.0 million upfront payment.

Senti Biosciences (NASDAQ:SNTI) (down USD 0.0302, 16.06%): Milestone Rights Replace Cash

Senti Biosciences (NASDAQ:SNTI) dropped 16.06% to USD 0.1578 in premarket trading on November 3, 2026, from roughly USD 0.1880 (calculated). No announcement dated November 2 or 3 was identified, and the move follows a late October disclosure of the merger closing on October 21, 2026.

Common stockholders received no cash at closing and instead one contingent value right per share, with payments capped at USD 60 million. About USD 16 million of convertible notes were exchanged for stock at USD 0.342 per share, and the screen price is about 53.9% below that (calculated). As a penny stock, it carries volatility, thin Liquidity and dilution risk.

Where Things Stand

These six names fell for different reasons, and for most no company announcement dated within the session window was identified. The common thread is capital structure: pending share exchanges at Jaguar Health, reverse splits at Arcadia, Medicus and Jaguar, a shelf at Niki and a merger that left Senti holders with milestone rights. Dates to watch are the November 6, 2026 Jaguar Health vote and the December 2, 2026 Medicus meeting.